Teva and Antares Pharma launch generic migraine drug

Pharmaceutical company Teva and US-based Antares Pharma have launched a generic version of Imitrex (sumatriptan succinate), which is used to treat migraines.

Imitrex injection, originally manufactured by GSK is used to treat acute migraines and acute cluster headaches in adults.

According to the American Migraine Study II, which is cited in Teva’s release on June 27, 36 million people suffer from migraines in the US and 85% of nearly 14,000 respondents experience throbbing pain.

Siggi Olafsson, president and chief executive of global generic medicines at Teva, said: “We are pleased to add sumatriptan injection to our growing portfolio through our successful partnership with Antares.”

Robert Apple, president and chief executive at Antares Pharma, said: “We are delighted to offer this product to patients in the US through our partner, Teva.”